The question of whether menopausal hormone therapy (MHT), often called hormone replacement therapy (HRT), influences long-term brain health has vexed researchers for more than two decades. Newer analyses suggest the answer hinges less on whether a woman takes hormones and more on when she starts them, what type she uses, and how long treatment continues.
Why Menopause Matters for the Brain
Estrogen is not just a reproductive hormone. It plays a role in glucose metabolism in the brain, synaptic plasticity, and cerebral blood flow. When ovarian estrogen production falls sharply during the menopause transition, some women experience changes in memory, sleep, and mood that overlap with early markers of cognitive aging.
According to the North American Menopause Society, roughly two-thirds of women report cognitive complaints during perimenopause, most of which resolve after the transition. But a smaller subset appears to remain at elevated risk for cognitive decline later in life, and researchers have long asked whether hormone therapy could protect — or harm — the aging brain.
The Timing Hypothesis
The dominant framework for interpreting the conflicting evidence is the “critical window” or timing hypothesis. It proposes that estrogen’s effect on the brain depends on the health of blood vessels and neurons at the time treatment begins.
Under this model, hormone therapy started near the onset of menopause — typically within about 10 years — may support cerebrovascular function. Starting the same therapy a decade or more after menopause, when subclinical vascular disease has already set in, may offer no benefit and could accelerate injury.
The landmark 2002 Women’s Health Initiative Memory Study reported an increased dementia risk among women who began combined estrogen-plus-progestin therapy in their late 60s or 70s. Later reanalyses and follow-up trials, including the Kronos Early Estrogen Prevention Study and the Early versus Late Intervention Trial with Estradiol, found no cognitive harm — and in some measures, modest benefit — when therapy began in women in their 50s.
What Newer Research Adds
A 2024 analysis published in Alzheimer’s & Dementia pooled data from more than 400,000 women in the UK Biobank and found that ever-use of hormone therapy was associated with a modestly lower risk of all-cause dementia when initiated close to menopause, but a higher risk when started 10 or more years afterward. The pattern held across dementia subtypes, including Alzheimer’s disease.
A separate Danish nationwide cohort study published in The BMJ in 2023 followed more than 55,000 women and reported that longer-duration use of combined estrogen-progestin therapy after age 55 was associated with a small but statistically significant increase in dementia diagnoses, even in women who initiated therapy near menopause. The authors emphasized that observational data cannot establish causation and that the absolute risk increase was small.
Together, these studies underscore how the age at initiation, formulation, and duration of therapy each shape the risk-benefit calculus.
Type of Hormone Therapy May Matter
Not all hormone regimens are equivalent. Research suggests that:
- Estrogen alone (prescribed for women who have had a hysterectomy) has generally shown a more neutral or favorable brain-health profile than combined therapy in observational studies.
- Combined estrogen-progestin therapy has shown a mixed picture, with some studies suggesting a higher dementia signal, particularly with longer use.
- Transdermal estradiol (patches or gels) delivers hormone through the skin and avoids first-pass liver metabolism, which some researchers hypothesize may lower cardiovascular and cognitive risk compared with oral formulations, though head-to-head trial data remain limited.
The Menopause Society’s 2022 position statement notes that the choice of formulation, dose, and route of administration should be individualized based on symptoms, cardiovascular risk profile, and personal history.
Menopause Type Also Plays a Role
Emerging research indicates that how menopause occurs may influence dementia risk independent of hormone therapy. A large 2024 study in JAMA Network Open found that women who experienced surgical menopause — removal of both ovaries — before age 45 had a measurably higher long-term risk of cognitive impairment compared with women who went through natural menopause at an average age. In this group, timely hormone therapy is often considered part of standard care until the typical age of natural menopause.
Early natural menopause, defined as onset before age 40 (premature ovarian insufficiency), has similarly been linked in observational research to increased dementia risk, particularly when hormones are not replaced.
What This Means in Practice
The evolving evidence does not deliver a simple yes-or-no answer on hormone therapy and dementia. Instead, it points toward a more individualized conversation between patients and clinicians. Factors that research suggests are worth weighing include:
- Age at menopause and current age
- Time since the final menstrual period
- Severity of vasomotor symptoms such as hot flashes and night sweats, which may themselves be linked to cardiovascular and cognitive outcomes
- Cardiovascular risk profile, including blood pressure, cholesterol, and diabetes
- Personal and family history of breast cancer, blood clots, or stroke
- Preferred formulation and route of administration
Beyond hormone therapy, well-established modifiable factors continue to dominate midlife brain-health guidance: regular physical activity, a heart-healthy dietary pattern such as the Mediterranean or MIND diet, adequate sleep, hearing protection, blood pressure control, and social and cognitive engagement.
The Bottom Line
Menopausal hormone therapy is neither a proven dementia treatment nor an established cause of it. Current research supports a nuanced view: initiating therapy near menopause, in a woman without contraindications and primarily for symptom relief, does not appear to increase — and may modestly lower — dementia risk in some analyses. Starting or continuing therapy well after menopause, particularly with combined regimens, is where signals of possible harm have emerged.
Women considering hormone therapy for menopausal symptoms should discuss the timing, type, and duration of any regimen with a clinician who is familiar with the latest evidence and can personalize the decision to their individual health picture.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.